Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. (Q54457707)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. |
scientific article |
Statements
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. (English)
1 reference
Tadeusz Pienkowski
1 reference
Istvan Lang
1 reference
Thomas Brodowicz
1 reference
Larisa Ryvo
1 reference
Zsuzsanna Kahan
1 reference
Richard Greil
1 reference
Semir Beslija
1 reference
Salomon M Stemmer
1 reference
Bella Kaufman
1 reference
Zanete Zvirbule
1 reference
Günther G Steger
1 reference
Bohuslav Melichar
1 reference
Daniela Sirbu
1 reference
Diethelm Messinger
1 reference
Christoph Zielinski
1 reference
Central European Cooperative Oncology Group
1 reference
10 January 2013
1 reference
14
1 reference
2
1 reference
125-133
1 reference
Identifiers
1 reference